Cohance Lifesciences Limited (BOM:543064)
India · Delayed Price · Currency is INR 429.40
-1.70 (-0.39%)
At close: Jun 1, 2026
Cohance Lifesciences Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 1,792 | 2,679 | 3,003 | 4,113 | 4,538 |
Depreciation & Amortization | 1,873 | 774.9 | 546 | 464.6 | 390.22 |
Other Amortization | - | - | - | - | 3.91 |
Loss (Gain) From Sale of Assets | -16.2 | 1.1 | 0.7 | 0.07 | -0.01 |
Loss (Gain) From Sale of Investments | -12.2 | -400.3 | -449.1 | -156.87 | -82.03 |
Stock-Based Compensation | -38.1 | 149.2 | 19.7 | - | - |
Provision & Write-off of Bad Debts | 10.7 | - | - | - | - |
Other Operating Activities | -134.2 | -0.6 | 8.5 | 93.58 | 389.52 |
Change in Accounts Receivable | 1,025 | -1,480 | 128.2 | 1,245 | -1,361 |
Change in Inventory | -945.8 | 741.2 | 816.1 | -293.93 | -823.37 |
Change in Accounts Payable | 128.4 | 417 | -225.2 | -357.99 | 232.04 |
Change in Other Net Operating Assets | - | - | - | -535.05 | 12.55 |
Operating Cash Flow | 3,683 | 2,882 | 3,848 | 4,572 | 3,300 |
Operating Cash Flow Growth | 27.82% | -25.11% | -15.84% | 38.54% | -13.74% |
Capital Expenditures | -2,199 | -1,557 | -518.8 | -2,859 | -751.87 |
Sale of Property, Plant & Equipment | 205.2 | - | - | 0.72 | 0.01 |
Cash Acquisitions | - | -7,280 | - | - | - |
Investment in Securities | -568.8 | 6,234 | -3,101 | 844.55 | -560.72 |
Other Investing Activities | 16.7 | 50.1 | -4.2 | 63.79 | -48.8 |
Investing Cash Flow | -2,546 | -2,553 | -3,624 | -1,950 | -1,361 |
Short-Term Debt Issued | - | 246.4 | - | - | - |
Total Debt Issued | - | 246.4 | - | - | - |
Short-Term Debt Repaid | -12.1 | - | -270.4 | -26.11 | -385.66 |
Long-Term Debt Repaid | -1,123 | -108.9 | -60 | -241.33 | -98.58 |
Total Debt Repaid | -1,135 | -108.9 | -330.4 | -267.43 | -484.24 |
Net Debt Issued (Repaid) | -1,135 | 137.5 | -330.4 | -267.43 | -484.24 |
Issuance of Common Stock | 324.3 | - | - | - | - |
Common Dividends Paid | - | - | - | -2,037 | -1,018 |
Other Financing Activities | -841.1 | -104.3 | -69.5 | -115.56 | -62.31 |
Financing Cash Flow | -1,652 | 33.2 | -399.9 | -2,420 | -1,565 |
Foreign Exchange Rate Adjustments | 38.9 | 19.9 | - | - | 0 |
Net Cash Flow | -475.1 | 381.7 | -175.7 | 202.39 | 373.82 |
Free Cash Flow | 1,484 | 1,325 | 3,329 | 1,713 | 2,548 |
Free Cash Flow Growth | 12.07% | -60.21% | 94.35% | -32.78% | -6.21% |
Free Cash Flow Margin | 6.45% | 11.06% | 31.66% | 12.78% | 19.30% |
Free Cash Flow Per Share | 3.88 | 5.18 | 13.08 | 6.73 | 10.01 |
Cash Interest Paid | - | 104.3 | 69.5 | 115.56 | 62.31 |
Cash Income Tax Paid | - | 834.4 | 1,100 | 1,458 | 1,843 |
Levered Free Cash Flow | -5,356 | 1,429 | 2,967 | 1,079 | 1,027 |
Unlevered Free Cash Flow | -5,123 | 1,506 | 3,014 | 1,159 | 1,066 |
Change in Working Capital | 207.6 | -321.4 | 719.1 | 57.68 | -1,940 |